REG - Intelligent Ultrasnd - Launch of ScanNav FetalCheck and its use in study

Intelligent UltrasoundAnnouncement

23/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231123:nRSW3853Ua&default-theme=true

RNS Number : 3853U  Intelligent Ultrasound Group PLC  23 November 2023

Intelligent Ultrasound announces launch of new gestational age estimation AI
software, ScanNav FetalCheck and its use in first field study

 

PRESS RELEASE 23 November 2023: Intelligent Ultrasound Group plc (AIM: IUG),
the 'classroom to clinic' ultrasound company specialising in artificial
intelligence (AI) software and simulation, is pleased to announce a new AI
development programme for gestational age estimation in prenatal care. ScanNav
FetalCheck scanning technology aims to enable a non-skilled or skilled user to
establish the gestational age (GA) accurately with minimal training.

 

Pregnant women are usually offered two routine ultrasound scans. The first at
11-14 weeks is performed to confirm viability of the fetus as well as the
gestational age to pinpoint the likely due date. A second scan at 18-20 weeks
focusses on detecting congenital abnormalities. Additional scans may be
offered to monitor high-risk or complex pregnancies.

 

Having an accurate gestational age is important in the management of
pregnancy, both to assess fetal growth and to inform treatment choice in the
event that complications are seen. However, accurate determination of GA is
difficult in low and middle -income countries (LMICs) as, currently, GA must
be measured by trained sonographers, and very few front-line healthcare
workers have the necessary skills.

 

Intelligent Ultrasound's ScanNav FetalCheck software aims to enable a
non-skilled user to get an accurate GA with minimal training and without the
need for an expensive high-end ultrasound machine. It has the potential to
transform antenatal care both in LMICs and in high income countries (HICs) by
allowing the age of the fetus to be assessed in a primary care setting where
women need it.

 

Intelligent Ultrasound is also pleased to announce that a leading university
in Africa has purchased four ScanNav FetalCheck systems as part of a trial to
evaluate biomarkers and other factors which affect the probability of
stillbirth.

 

ScanNav FetalCheck is currently not licenced for clinical use.

 

Aris Papageorghiou, Professor of fetal medicine at the University of Oxford
said:

"Accurate estimation of gestational age is crucial for prenatal care: all
aspects depend on knowledge of how far along the pregnancy journey a woman and
her fetus are. In many low-income settings this is just not available, chiefly
due to unavailability of expensive ultrasound equipment and trained staff. In
this project, hand-held ultrasound and AI technology are being paired to
overcome these roadblocks - this is disruptive technology that has the
potential to allow better pregnancy care for all women."

 

Nicholas Sleep, COO at Intelligent Ultrasound said:

"The use of ScanNav FetalCheck in this first field study is a testament to the
ease of use of our new AI software. Our mission is to make ultrasound easier
to learn and simpler to use. This is the next step on our journey to achieving
this and putting ultrasound into the hands of front-line health
practitioners."

 

ENDS

 

Enquiries:

 

 Intelligent Ultrasound Group plc   www.intelligentultrasound.com (http://www.intelligentultrasound.com)
 Stuart Gall, CEO                   Tel: +44 (0)29 2075 6534
 Helen Jones, CFO

 Cavendish Securities Plc

 (Nominated advisor and broker)
 Giles Balleny (Corporate Finance)  Tel: +44 (0)20 7397 8900

 Nigel Birks (ECM)

 Dale Bellis (Sales)

 

  TB Cardew - PR Advisors   Intelligentultrasound@tbcardew.com (mailto:Intelligentultrasound@tbcardew.com)

  Ed Orlebar                Tel: +44 (0)7738 724630
  Allison Connolly                                                    Tel: +44 (0)7587 453955
  Emma Pascoe-Watson                                                  Tel: +44 (0)7774 620415
  Jessica Pilling                                                     Tel: +44 (0)7918 584573

 

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,500 simulators have been sold to over 750 medical
institutions around the world.

 

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
HealthCare's SonoLyst software that is incorporated in their Voluson Expert
22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound-guided needling and incorporates ScanNav
Anatomy PNB.

 

www.intelligentultrasound.com (http://www.intelligentultrasound.com/)

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the
FDA, but is not available for sale in any other territory requiring government
approval for this type of product.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLBTBPTMTMTBAJ